Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Possible Advantage of Twice-Daily 6-Mercaptopurine Dosing in Children with Acute Lymphoblastic Leukemia (ALL).

Thaddeus Y. Carson, BSE, Beverly A. Bell, MD, Gary Erdmann, PhD, Bruce Bostrom, MD, Bruce M. Camitta, MD, Meenakshi Devidas, PhD

Blood (2007) 110 (11): 851.

https://doi.org/10.1182/blood.V110.11.851.851

Published: 2007

Journal Articles

Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201

Allen R. Chauvenet, Paul L. Martin, Meenakshi Devidas, Stephen B. Linda, Beverly A. Bell, Joanne Kurtzberg, Jeanette Pullen, Mark J. Pettenati, Andrew J. Carroll, Jonathan J. Shuster, Bruce Camitta

Blood (2007) 110 (4): 1105–1111.

https://doi.org/10.1182/blood-2006-12-061689

Published: 2007

Includes: Supplemental data

Journal Articles

A Report of the Event Free Survival (EFS) for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) Treated on Pediatric Oncology Group (POG) Protocol 9605.

Beverly A. Bell, MD, Sharon B. Abish, MD, Allen Chauvenet, MD, Joanne Kurtzberg, MD, Jeanette Pullen, MD, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Bruce M. Camitta, MD

Blood (2005) 106 (11): 875.

https://doi.org/10.1182/blood.V106.11.875.875

Published: 2005

Journal Articles

Thrombotic and Hemorrhagic Events for Patients on Pediatric Oncology Group (POG) Protocols 9201, 9605, 9406.

Megan A. Rice, Beverly A. Bell, MD, Allen Chauvenet, MD, Joanne Kurtzberg, MD, Sharon B. Abish, MD, Jeanette Pullen, MD, Meenakshi Devidas, PhD, Bruce M. Camitta, MD

Blood (2005) 106 (11): 880.

https://doi.org/10.1182/blood.V106.11.880.880

Published: 2005

Journal Articles

A Report of the Event-Free Survival (EFS) and Neurotoxicity for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) on Pediatric Oncology Group (POG) Protocol 9405.

Stephen Rodes, BS, Beverly A. Bell, MD, Sharon B. Abish, MD, Jeanette Pullen, MD, Allen Chauvenet, MD, Joanne Kurtzberg, MD, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Bruce M. Camitta, MD

Blood (2005) 106 (11): 882.

https://doi.org/10.1182/blood.V106.11.882.882

Published: 2005

NARROW

Possible Advantage of Twice-Daily 6-Mercaptopurine Dosing in Children with Acute Lymphoblastic Leukemia (ALL).

Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201

A Report of the Event Free Survival (EFS) for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) Treated on Pediatric Oncology Group (POG) Protocol 9605.

Thrombotic and Hemorrhagic Events for Patients on Pediatric Oncology Group (POG) Protocols 9201, 9605, 9406.

A Report of the Event-Free Survival (EFS) and Neurotoxicity for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) on Pediatric Oncology Group (POG) Protocol 9405.

Email alerts

ASH Publications

American Society of Hematology

Possible Advantage of Twice-Daily 6-Mercaptopurine Dosing in Children with Acute Lymphoblastic Leukemia (ALL).

Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201

A Report of the Event Free Survival (EFS) for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) Treated on Pediatric Oncology Group (POG) Protocol 9605.

Thrombotic and Hemorrhagic Events for Patients on Pediatric Oncology Group (POG) Protocols 9201, 9605, 9406.

A Report of the Event-Free Survival (EFS) and Neurotoxicity for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) on Pediatric Oncology Group (POG) Protocol 9405.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only